Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia

  • STATUS
    Not Recruiting
  • End date
    Nov 8, 2024
  • participants needed
    346
  • sponsor
    Gilead Sciences
Updated on 5 March 2022
hydroxyurea
cytarabine
ejection fraction
gilbert's syndrome
daunorubicin
idarubicin
azacitidine
venetoclax
TP53

Summary

The primary objective of this study is to compare the efficacy of magrolimab + azacitidine versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival (OS).

Details
Condition Acute Myeloid Leukemia
Treatment cytarabine, Idarubicin, Azacitidine, Daunorubicin, venetoclax, Magrolimab, Steroidal Eye Drops
Clinical Study IdentifierNCT04778397
SponsorGilead Sciences
Last Modified on5 March 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note